Last reviewed · How we verify
SIM0270
SIM0270 is a small molecule inhibitor targeting a specific molecular pathway involved in disease pathogenesis, though the exact mechanism requires further clarification.
At a glance
| Generic name | SIM0270 |
|---|---|
| Also known as | SCR6852 |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
SIM0270 is an investigational drug in Phase 3 development by Jiangsu Simcere Pharmaceutical. Limited public information is available regarding its precise molecular mechanism and target. Additional clinical trial data would be needed to fully characterize its mechanism of action.
Approved indications
Common side effects
Key clinical trials
- An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants (PHASE1)
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE) (PHASE3)
- Evaluate the Effects of Food on the Pharmacokinetics of SIM0270 (PHASE1)
- Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer (PHASE1)
- Mass Balance Clinical Trial of SIM0270 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |